Company intelligence / Profile preview
Zocentive
Albuquerque, New Mexico, United Stateszocere.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Zocere developed an injectable neuroprotectant peptide drug licensed from University of New Mexico technology, targeting acute neurological injuries such as stroke and concussion. No published clinical results are available; development status after initial preclinical work remains unclear[5].
- Therapeutic areas
- Neurology
- Modalities
- PeptidesSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of New Mexico/STC.UNM (licensing partner for STEP peptide technology)[5]
Beyond the preview
Go deeper on Zocentive.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zocentive.